What do you think of today's 20% drop in $NVOstock ? Will you buy?

Novo Nordisk's shares fell sharply today following news that the weight-loss drug CagriSema achieved lower than expected efficacy in trials. I don't have $NVOstock in my portfolio, but I want to focus on this company now.

In the past month alone, $NVOstock is down more than 11%, and according to the Bulios Fair Price Index, the stock is currently slightly undervalued. Recently @edin_medinmentioned this stock , and frankly I'm starting to think about buying it too. If $NVO stock were to drop another 5, 6%, I would buy.

Are you buying $NVOstock on the current decline?

I recently dissected $NVOhere . I decided to buy shares of this company ahead of its earnings. However, this investment did not work out as I expected. After the mediocre results and the US election results, the stock price rose to $116, however, after a short time it plummeted down to $106. Personally, I expected the price to stay at least at the $110 level, which is where I...
Read more

The anti-obesity drug industry was in 2023 valued at $5.6 billion and will exhibit a CAGR of 27% between 2024 and 2032 (expert opinion).

$LLY, $NVO and others are creating drugs like - Ozempic, Wegovy, Mounjaro and Zepbound - These are blockbusters in terms of weight loss market in my opinion. But which companies may have the best chance to take the biggest bite of that...
Read more

📆 Overview of interesting things for the upcoming week! 🚀

This week I will be watching mostly company results. With the investor sentiment from last week, I think wonders will happen when the markets announce earnings.

🔍 Monday:
ISM Services PMI - This index measures economic activity in the service sector and often serves as an indicator of overall economic health.

Earnings: Befor...
Read more

Analysts at Berenberg have raised their estimates for the global obesity market to $150 billion by 2035, up from $125 billion previously. This revision is the result of positive data on co-morbidities and advances in competing studies. Berenberg recommends buying shares of $LLY and Zealand Pharma, while he recommends holding on to shares of $NVO.

What are your thoughts on...
Read more

📊 Investment Calendar 📆

Earnings season is in full swing, and with it comes more exciting news. Here is a summary of the news I will be following.

Monday: I'll only be watching company results.

📈 Earnings: Before the markets open, I'll be watching Domino's Pizza $DPZ, SoFi Technologies $SOFI and ON Semiconductor $ON. After the close, just the results of Paramount $PARA and Logit...
Read more

📈💡 New and interesting player on the pharmaceutical market! 💊🔍

One of the most discussed topics in the pharmaceutical market is the treatment of obesity and diabetes. Only two companies are behind many successful drugs such asOzempic, Rybelsus and Saxenda: Novo Nordisk $NVO and Eli Lilly $LLY. These companies have had significant success in the treatment of diabetes and...
Read more

Novo Nordisk A/S is a Danish company that recently introduced a cure for obesity. Shares of $NVO are up more than 20% in the past month and more than 40% this year. For me, the company is going in a good direction and the business is also great, as obesity is really affecting a lot of people at the moment and if the development of this drug goes as well in the future as it has...
Read more

Novo Nordisk $NVO closed the day yesterday with a larger market capitalisation than LVMH, making it Europe's largest public company. Novo's share price rose 1.9 percent to $189.3, giving the company a market capitalization of $423 billion.

Do you have shares of $NVO in your portfolio?